{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:12:25Z","timestamp":1793643145842,"version":"4.5.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.rpth.2024.102576","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:52:19Z","timestamp":1727128339000},"page":"102576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-8509","authenticated-orcid":false,"given":"Sylvain","family":"Lamoine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Fourneyron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian","family":"Teissandier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Talon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sinegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102576_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102576_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"Hassan","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0034-1381232","article-title":"The history of hemophilia","volume":"40","author":"Franchini","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102576_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0268-960X(03)00038-9","article-title":"Prophylactic factor replacement in hemophilia","volume":"18","author":"Carcao","year":"2004","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2024.102576_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/hae.12079","article-title":"Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review","volume":"19","author":"Schrijvers","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102576_bib6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2024.102576_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102576_bib8","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102576_bib9","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102576_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102576_bib11","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102576_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102576_bib13","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102576_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0040-1718410","article-title":"Long-term antithrombotic treatments prescribed for cardiovascular diseases in patients with hemophilia: results from the French registry","volume":"121","author":"Guillet","year":"2021","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2024.102576_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12959-016-0097-x","article-title":"Comorbidities of cardiovascular disease and cancer in hemophilia patients","volume":"14","author":"Wang","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2024.102576_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1160\/TH12-05-0332","article-title":"Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients","volume":"109","author":"Fransen van de Putte","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib17","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1111\/hae.13069","article-title":"How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population","volume":"22","author":"Berger","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102576_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/hae.13585","article-title":"Risk factors for cardiovascular disease in children and young adults with haemophilia","volume":"24","author":"Limjoco","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102576_bib19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5482\/HAMO-16-09-0037","article-title":"Management of cardiovascular disease in aging persons with haemophilia","volume":"37","author":"Schutgens","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2024.102576_bib20","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1055\/s-0039-1698756","article-title":"Catheter ablation for atrial fibrillation in patients with hemophilia or von Willebrand disease","volume":"3","author":"Van Der Valk","year":"2019","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2024.102576_bib21","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance","volume":"7","author":"Schutgens","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.rpth.2024.102576_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ejh.13490","article-title":"Emicizumab treatment: impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)","volume":"105","author":"Nougier","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2024.102576_bib23","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1055\/s-0041-1725009","article-title":"Ex\u00a0vivo prediction of comprehensive coagulation potential using simulated blood concentrations of emicizumab in patients with acquired hemophilia A","volume":"121","author":"Takeyama","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","article-title":"Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis","volume":"110","author":"Yada","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2024.102576_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors\u2014a single-center cohort","volume":"66","author":"Barg","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2024.102576_bib27","article-title":"In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype","volume":"7","author":"Verhagen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib28","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In\u00a0vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib29","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102576_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A\u00a0multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102576_bib32","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"issue":"5\u20136","key":"10.1016\/j.rpth.2024.102576_bib52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.rpth.2024.102576_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.clinthera.2017.04.007","article-title":"International normalized ratio is significantly elevated with rivaroxaban and apixaban drug therapies: a retrospective study","volume":"39","author":"Ofek","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.rpth.2024.102576_bib34","first-page":"2317","article-title":"Safe and successful surgical outcome in persons with hemophilia A with and without inhibitors treated with emicizumab: a large, single center, real-world experience","volume":"12","author":"Castaman","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rpth.2024.102576_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29041","article-title":"Surgery with emicizumab prophylaxis for two paediatric patients with severe haemophilia A with inhibitors","volume":"68","author":"Lockhart","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2024.102576_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/trf.15560","article-title":"Impact of Rivaroxaban plasma concentration on perioperative red blood cell loss","volume":"60","author":"Kaserer","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.rpth.2024.102576_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.717939","article-title":"Automated thrombin generation assay for Rivaroxaban, Apixaban, and edoxaban measurements","volume":"8","author":"Meihandoest","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.rpth.2024.102576_bib38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A\u00a0modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"Ogiwara","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2024.102576_bib39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.thromres.2008.09.011","article-title":"Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A","volume":"123","author":"van Veen","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102576_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jth.13674","article-title":"Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists","volume":"15","author":"de Koning","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib42","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2516.2009.02190.x","article-title":"Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy","volume":"16","author":"Gilmore","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102576_bib43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2022.12.023","article-title":"The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation","volume":"21","author":"Bowyer","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib44","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1055\/s-0043-1769788","article-title":"Pharmacodynamics monitoring of emicizumab in patients with hemophilia A","volume":"123","author":"Bertaggia Calderara","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib45","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1046\/j.1538-7836.2003.00209.x","article-title":"A\u00a0modified thrombin generation test for the measurement of factor VIII concentrates","volume":"1","author":"Mcintosh","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib46","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtha.2023.03.007","article-title":"In\u00a0vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays","volume":"21","author":"Lund","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.thromres.2018.10.005","article-title":"The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation","volume":"171","author":"Bloemen","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102576_bib48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/rth2.12044","article-title":"Assessment of the effect of direct oral anticoagulants dabigatran, Rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay","volume":"1","author":"Artang","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102576_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102576_bib50","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102576_bib51","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1111\/hae.14272","article-title":"Emicizumab improves thrombus formation of type 2A von Willebrand disease under high shear condition","volume":"27","author":"Yaoi","year":"2021","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:22:49Z","timestamp":1732234969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2475037924002711"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102576","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102576"}}